SNMMI sent a letter to the FDA recommending initiation of a fast-track review of Cyclopharm's Technegas agent used for nuclear medicine ventilation/perfusion lung scans. Speedy approval of Technegas is vital because of the decrease in V/Q studies focused on the ventilation portion since the COVID-19 pandemic started, SNMMI said.
SNMMI backs Technegas fast-track review for V/Q scans
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.